Coronary Heart Disease Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor Insights From the Platelet Inhibition and Patient Outcomes Trial
نویسندگان
چکیده
Shaun G. Goodman, MD, MSc; Robert Clare, MS; Karen S. Pieper, MS; José C. Nicolau, MD; Robert F. Storey, MD; Warren J. Cantor, MD; Kenneth W. Mahaffey, MD; Dominick J. Angiolillo, MD, PhD; Steen Husted, MD; Christopher P. Cannon, MD; Stefan K. James, MD, PhD; Jan Kilhamn, MD, PhD; P. Gabriel Steg, MD; Robert A. Harrington, MD; Lars Wallentin, MD, PhD; on behalf of the Platelet Inhibition and Patient Outcomes (PLATO) Trial Investigators
منابع مشابه
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
BACKGROUND The clinical significance of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear. METHODS AND RESULTS We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor in a prespecified, nonrandomized...
متن کاملCoronary Heart Disease Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis
Background—Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting. Ticagrelor, a reversible oral P2Y12-receptor antagonist, provides faster, greater, and more consistent platelet inhibition than clopidogrel and may be useful for patients with acute ST-segment elevation (STE) ACS and planned primary percutaneous coronary intervent...
متن کاملTo Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question
T he treatment of patients presenting with non-STsegment elevation myocardial infarction (NSTEMI) continues to evolve. As advancing technical capabilities in the cardiac catheterization lab have expanded percutaneous revascularization options, medical treatments have also continued to progress, offering ongoing improvements in outcomes. The 2014 American Heart Association/American College of Ca...
متن کاملTicagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
BACKGROUND Patients with chronic obstructive pulmonary disease (COPD) experiencing acute coronary syndromes (ACS) are at high risk for clinical events. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which ma...
متن کاملCoronary Heart Disease Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Background—Reduced renal function is associated with a poorer prognosis and increased bleeding risk in patients with acute coronary syndromes and may therefore alter the risk-benefit ratio with antiplatelet therapies. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor compared with clopidogrel reduced the primary composite end point of cardiovascular death, myocardial inf...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2012